Skip to main content

Table 2 Clinical and virological relapses after cessation of nucleos(t)ide analogues in patients with negative HBeAg and undetectable viral DNA at the end of treatment

From: Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy

All (N = 140)

 

First year

Second year

Virological relapse

62.0% (95% CI, 53.5–70.6%)

79.2% (95% CI, 70.9–86.4%)

Clinical relapse

28.4% (95% CI, 21.2–37.5%)

42.9% (95% CI, 34.1–52.8%)

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us